One To Watch

Arcellx

A clinical-stage cell therapy company developing next-generation CAR T-cell therapies for cancer, led by a BCMA-targeted program in multiple myeloma.

Company Overview

Arcellx develops engineered T-cell therapies that redirect a patient’s immune system to recognize and eliminate cancer. Its lead program, anitocabtagene autoleucel (anito-cel; formerly CART-ddBCMA), targets BCMA in relapsed or refractory multiple myeloma.

The company’s strategy is to pair a differentiated binding domain with operational execution that supports broad clinical adoption. A second BCMA program, ACLX-001, is positioned as a next-wave candidate in the same target space.

Headquarters and Global Presence

Arcellx operates across two US hubs:
Redwood City, California (corporate headquarters) and Rockville, Maryland (operations footprint).

Clinical development is conducted through multinational trial networks in myeloma centers. Manufacturing and supply are organized to support late-stage and commercial readiness for a CAR T product.

Founding and History

Arcellx was founded to develop engineered cell therapies using novel synthetic protein binders. The company advanced its BCMA CAR T program into the clinic and later built a strategic partnership with Kite, a Gilead company, to accelerate development and commercialization.

In February 2026, Gilead announced a definitive agreement to acquire Arcellx, reflecting the strategic importance of anito-cel within the cell therapy landscape.

Therapy Areas and Focus

Arcellx’s disclosed focus is oncology, led by hematologic malignancies:
Multiple myeloma is the priority indication, with BCMA as the anchor target.

The company also highlights broader platform applicability to additional targets and settings over time. Near-term value concentration remains in the myeloma franchise.

Technology Platforms and Modalities

Arcellx’s core platform is its D-domain binder technology. D-domains are compact synthetic proteins used as antigen-binding elements in its CAR constructs.

Program architecture emphasizes:
Targeted binding design, durable CAR activity, and a clinical profile suited to repeatable real-world use.

Key Personnel

Rami Elghandour: Chairman and Chief Executive Officer
David Hilbert, PhD: Founder; Chief Technical Officer

Strategic Partnerships

Arcellx’s central partnership is with Kite (Gilead) for anito-cel. The collaboration supports late-stage execution, manufacturing scale and eventual commercialization planning.

The February 2026 acquisition agreement effectively brings Arcellx’s lead program under Gilead’s oncology and cell therapy platform.

FAQ Section

Arcellx develops CAR T-cell therapies built around its proprietary D-domain binders. The platform is intended to enable compact, high-affinity binding elements that can support potent CAR designs.

The thesis is that binder design and construct architecture can translate into better clinical durability and operational practicality.

Arcellx is an oncology company with its near-term focus in hematologic malignancies. The lead commercial opportunity is multiple myeloma.

The platform is positioned as expandable to additional targets, but the current center of gravity is myeloma.

Key disclosed programs include:

anitocabtagene autoleucel (anito-cel; CART-ddBCMA): BCMA CAR T in multiple myeloma, including registrational development
ACLX-001: BCMA-targeted program positioned as an additional myeloma asset

February 2026: Gilead announced a definitive agreement to acquire Arcellx, building on the existing Kite–Arcellx collaboration.

The announcement centered on maximizing the long-term potential of anito-cel in multiple myeloma and accelerating a path toward broad availability.

Arcellx and its partner have highlighted deep response rates and durability from early clinical experience in relapsed or refractory multiple myeloma. The company has also emphasized a tolerability profile positioned for broad specialist adoption.

The value question is whether outcomes remain strong and reproducible in larger, later-stage populations and earlier lines of therapy.

Near-term milestones are driven by the registrational pathway for anito-cel, including completion and readout of late-stage studies and alignment on submission strategy.

Clinical progression follows the standard sequence of Phase I, Phase II and Phase III, with pivotal-stage execution and manufacturing readiness as the gating factors for approval and launch.

Key value drivers include:

late-stage performance of anito-cel in multiple myeloma and its competitiveness versus established BCMA CAR T options
scalability and consistency of manufacturing and delivery logistics
success expanding into earlier-line myeloma settings where market size is larger
evidence that the D-domain platform can generate additional differentiated CAR programs beyond BCMA

Want to Update your Company's Profile?